Cancer clinical trials shouldn’t discriminate—but they do

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In 2004, doctors told my husband Mike there was nothing more they could do—the pancreatic cancer he was diagnosed with would soon take his life. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Erin Miller
Development manager, Lazarex Cancer Foundation
Table of Contents

YOU MAY BE INTERESTED IN

Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet. 
Erin Miller
Development manager, Lazarex Cancer Foundation

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login